Informing Pain Treatment Using Pharmacogenomic Analysis

Description

This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.

Conditions

Analgesia, Cancer, CYP2D6

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.

C-PAIN: Catalyzing Pharmacogenomic Analysis for Informing Pain Treatment

Informing Pain Treatment Using Pharmacogenomic Analysis

Condition
Analgesia
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States, 60637

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Persons receiving ongoing oncology care at the University of Chicago Medical Center for whom near-future pain opioid pain medication therapy is anticipated
  • * Subjects must be at least 18 years of age.
  • * Subjects taking an opioid at the time of enrollment, or within the past 30 days
  • * Subjects who are currently undergoing palliative radiation
  • * Subjects who have undergone, or are being actively considered for, bone marrow, liver or kidney transplantation.
  • * Subjects with a history of or active blood cancer (e.g., leukemia).
  • * Chronic kidney disease, as defined by Glomerular filtration rate (GFR) \< 30/mL/min/1.73m2, due to the risk of decreased drug excretion.
  • * Liver dysfunction, as defined by the following laboratory values, due to the risk of decreased drug metabolism: Total bilirubin greater than or equal to1.5 mg/dL, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) greater than or equal to 2.5 X upper limit of normal\*. (\*Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \\ greater than or equal to 5 X upper limit of normal if hepatic metastases are present).
  • * Inability to understand and give informed consent to participate in the opinion of the investigator
  • * Subjects who are known to be pregnant at the time of enrollment
  • * Subjects who are enrolled in other Pharmacogenomic (PGx) studies

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Chicago,

Peter H O'Donnell, PRINCIPAL_INVESTIGATOR, University of Chicago

Study Record Dates

2028-08